CLOV
Clover Health Investments, Corp.
CLOV has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
CLOV Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Healthy | |
| Strong |
CLOV's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
CLOV PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 61x | $4.88 | — |
| Cheap | 483x | $4.83 | -1% |
| Fair | 485x | $4.85 | -0.6% |
| Expensive | 487x | $4.87 | -0.2% |
| Current | 488x | $4.88 | — |
Historical ranges are pointers, not guarantees.
CLOV has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
CLOV Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Improving | |
| Limited | |
| High |
CLOV has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
CLOV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.08 | +702% |
| Q3 2026 | $0.01 | +$0.12 |
| Q2 2026 | -$0.05 | +$0.03 |
| Q1 2026 | -$0.12 | -$0.07 |
| Q4 2025 | -$0.17 | -$0.08 |
| Q3 2025 | -$0.11 | +$0.07 |
| Q2 2025 | -$0.08 | +$0.17 |
| Q1 2025 | -$0.05 | +$0.28 |
| Q4 2024 | -$0.09 | +$0.35 |
CLOV has returned to profit: it earned $0.01 per share over the past year, after losing money the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over CLOV on earnings, with more consistent year-over-year improvement.
CLOV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $759.3M | +53% |
| Q2 2026 | $743.2M | +56% |
| Q1 2026 | $749.2M | +62% |
| Q4 2025 | $487.7M | +45% |
| Q3 2025 | $496.7M | +50% |
| Q2 2025 | $477.6M | +34% |
| Q1 2025 | $462.3M | +33% |
| Q4 2024 | $337M | -34% |
CLOV has the edge over NVO on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0.8% | +5.8 points |
| Q2 2026 | 3.8% | +6 points |
| Q1 2026 | 3.6% | +3.9 points |
| Q4 2025 | -10% | -3.7 points |
| Q3 2025 | -4.9% | -2.3 points |
| Q2 2025 | -2.2% | -4.2 points |
| Q1 2025 | -0.3% | +6.3 points |
| Q4 2024 | -6.4% | +6.5 points |
CLOV's operating margin was 0.8% last quarter, up 5.8 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over CLOV on profitability, with a higher operating margin.
CLOV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $69.5M | +509% |
| Q2 2026 | $24.5M | +406% |
| Q1 2026 | $107M | +$123.5M |
| Q4 2025 | -$68.7M | +$17.4M |
| Q3 2025 | $11.4M | -77% |
| Q2 2025 | $4.8M | -89% |
| Q1 2025 | -$16.5M | -165% |
| Q4 2024 | -$86.1M | +$142.9M |
CLOV's free cash flow has turned positive again: $132M over the past year, against −$86M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
CLOV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.2% | +12M shares |
| 1 year | +8.7% | +44.7M shares |
| 3 years | +16% | +76.7M shares |
| 5 years | +34% | +143M shares |
CLOV has 557M diluted shares, up 8.7% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $1,000 |
| Q2 2025 | — |
| Q1 2025 | $18.3M |
| Q4 2024 | — |
CLOV hasn't bought back shares in the past year.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over CLOV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
CLOV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -18.4x | Net Cash |
CLOV has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
CLOV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.6 | Neutral |
| Stochastic | 56.9 | Neutral |
CLOV's weekly RSI is 60 (neutral) and its Stochastic is 57 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
CLOV PE vs Healthcare Sector
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
CLOV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.61 | 5.9% above |
| 20 week MA | $4.55 | 7.3% above |
| 50 week MA | $3.47 | 41% above |
| 100 week MA | $3.36 | 45% above |
| 200 week MA | $2.41 | 102% above |
CLOV has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
CLOV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.2 | $14.9 | +46% |
| 2021 | $14.9 | $4.20 | -72% |
| 2022 | $4.20 | $0.92 | -78% |
| 2023 | $0.92 | $0.95 | +3.3% |
| 2024 | $0.95 | $3.26 | +243% |
| 2025 | $3.26 | $2.51 | -23% |
| 2026 YTD | $2.51 | $4.88 | +94% |
CLOV has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.